The selling is modest and likely liquidity-driven. Monitor for any upcoming corporate events (e.g., pipeline milestones or earnings) that could explain the timing, but this cluster does not warrant a defensive trade on its own.
ABEO drugs
ABEO drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Jun 16 $5.65entry
- T+1 · 5mo ago 0.00%α +1.25% · $5.65
- T+5 · 5mo ago +1.24%α +3.47% · $5.72
- T+20 · 4mo ago +24.96%α +24.76% · $7.06
- T+60 · due 2mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Five ABEO insiders, including the CEO and CFO, sold a total of $407K in shares over a 7-day window. The selling represents 0.13% of market cap, a modest amount that is typical of routine diversification or liquidity needs rather than a strong negative signal.
Key Financial Metrics
Key Facts
- CEO Vishwas Seshadri sold 31.9K shares ($169K) on June 9.
- CFO Joseph Vazzano sold 13.4K shares ($71K) on June 9.
- Director Christine Silverstein sold 18.2K shares ($104K) on June 15.
- Total insider sales of $407K represent 0.13% of ABEO's $322M market cap.
- All sales were open-market transactions; no 10b5-1 plan disclosures are noted.
Financial Impact
Insider sales of $407K total, modest relative to $322M market cap (0.13%).
Risk Factors
- Insider selling could accelerate if negative news emerges.
- Biotech sector volatility may amplify any sentiment shift.
- Further selling from C-suite could signal waning confidence.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ABEO-1781728397497 |
Track record
29 reports on ABEO
4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +15.24% at T+20 after the Sep 29, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry price pending
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $2.30 Now $2.60 +13.04% settles Nov 17
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $2.29 to $2.42 Now $2.60 +13.54% ▲ +5.68% +6.04% vs SPY
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $2.54 to $2.46 Now $2.60 −2.36% ▲ +3.35% +2.98% vs SPY
- Nov 9, 20267d ago Press Release Mixed 6/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $4.17 to $2.54 Now $2.60 −37.65% ▼ −39.09% −41.46% vs SPY
- Oct 23, 202624d ago SC 13D Bullish 6/10 Entry $4.40 to $4.31 Now $2.60 −40.91% ▼ −2.05% −2.76% vs SPY
- Sep 29, 20266w ago Insider Cluster Bearish 4/10 Entry $5.25 to $5.01 Now $2.60 +50.48% ▲ +4.57% +4.75% vs SPY
- Sep 18, 20268w ago Press Release Bullish 6/10 Entry $5.57 to $5.67 Now $2.60 −53.32% ▲ +1.80% +0.24% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers